BioLife Solutions (FRA:BJX1) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BJX1 BioLife Solutions Inc FRA:BJX1
71 GF Score
Price €26.80
GF Value €25.92
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioLife Solutions Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BioLife Solutions Valuation Rank Related Terms

FRA:BJX1
71GF Score
BioLife Solutions Inc FRA:BJX1
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioLife Solutions (FRA:BJX1) Overvalued in 2026?

Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued. The current stock price of €26.80 is trading 3.4% above its estimated GF Value™ of €25.92. GuruFocus considers BioLife Solutions to be Fairly Valued.

Key valuation signals for FRA:BJX1:

  • Valuation Rank:
  • GF Value™: €25.92 vs. price of €26.80 (3.4% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the FRA:BJX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioLife Solutions Business Description

Other Exchanges BLFS:USA
Address 3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
71GF Score

Get the complete analysis for FRA:BJX1

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.80
Price
€25.92
GF Value